-
1 month ago | 
cancernetwork.com | Rohit Gosain |Rahul Gosain |Alan Bryce
Experts give an overview of the treatment landscape in prostate cancer as of 2025.
-
1 month ago | 
cancernetwork.com | Rohit Gosain |Rahul Gosain |Alan Bryce
Experts discuss the role of PARP inhibitors in prostate cancer treatment, exploring their mechanisms, clinical benefits, and how they fit into current therapeutic strategies.
-
1 month ago | 
cancernetwork.com | Rohit Gosain |Rahul Gosain |Alan Bryce
Experts discuss how to decide which robotic prostatectomy (RP) approach to utilize, considering factors such as patient characteristics, surgical outcomes, and the latest clinical evidence.
-
1 month ago | 
cancernetwork.com | Rohit Gosain |Rahul Gosain |Alan Bryce
Experts discuss considerations for other androgen receptor inhibitors, highlighting their role in treatment strategies and how they impact patient outcomes in prostate cancer.
-
Apr 19, 2024 | 
nature.com | Neal Shore |Emmanuel S. Antonarakis |Rana R. McKay |Alan Bryce
Correction to: Prostate Cancer and Prostatic Diseases https://doi.org/10.1038/s41391-024-00803-5All authors have requested a correction to include the middle initials for all authors. Neal Shore1,*, Emmanuel Antonarakis2, Ashley Ross3, Catherine Marshall4, Kelly Stratton5, Adanma Ayanambakkam5, Michael Cookson5, Rana McKay6, Alan Bryce7 and Marina Kaymakcalan8should read:Neal D. Shore, MD, FACS^1^, Emmanuel S. Antonarakis, MD 2, Ashley E. Ross, MD, PhD 3, Catherine H. Marshall, MD^4, Kelly L.
-
Mar 5, 2024 | 
urotoday.com | Alan Bryce
Read the Full Video TranscriptAlicia Morgans: Hi. I'm so excited to be here at ASCO GU 2024, where I am speaking with Dr. Alan Bryce, who is the Chief Clinical Officer of City of Hope, Arizona, which is the new clinic that's been developed outside of Phoenix. Thank you so much for being here with me today. Alan Bryce: Pleasure to be back. Nice to see you.
-
Feb 27, 2024 | 
urotoday.com | Alan Bryce
Read the Full Video TranscriptElena Castro: Hello, my name is Elena Castro. I'm a medical oncologist in Madrid, Spain, and today I'm joined by Dr. Alan Bryce. This discussion is part of an educational series highlighting the state-of-the-art, interdisciplinary management of prostate cancer.
-
Nov 10, 2023 | 
urotoday.com | Alan Bryce
Alan Bryce discusses the PSMAfore and other trials with Zach Klaassen. The trial, focusing on lutetium treatment for metastatic castration-resistant prostate cancer (mCRPC) in a pre-chemotherapy setting, shows a significant radiographic progression-free survival (rPFS) benefit. Dr. Bryce highlights the importance of selecting appropriate patients through PSMA PET scans.
-
Nov 10, 2023 | 
urotoday.com | Alan Bryce
Alan Bryce discusses the PSMAfore and other trials with Zach Klaassen. The trial, focusing on lutetium treatment for metastatic castration-resistant prostate cancer (mCRPC) in a pre-chemotherapy setting, shows a significant radiographic progression-free survival (rPFS) benefit. Dr. Bryce highlights the importance of selecting appropriate patients through PSMA PET scans prior to initiating treatment in clinical practice.
-
Nov 10, 2023 | 
urotoday.com | Alan Bryce
Alan Bryce discusses the PSMAfore and other trials with Zach Klaassen. The trial, focusing on lutetium treatment for metastatic castration-resistant prostate cancer (mCRPC) in a pre-chemotherapy setting, shows a significant radiographic progression-free survival (rPFS) benefit. Dr. Bryce highlights the importance of selecting appropriate patients through PSMA PET scans prior to initiating treatment in clinical practice.
